Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
AASTROM BIOSCIENCES (NQ: ASTM)
0.5573 USD  -0.0127 (-2.23%)
Streaming Delayed Price  /  Updated: 10:44 AM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Stories about AASTROM BIOSCIENCES
 
< Previous 1 2 3 4 5 6 7 Next >
Aastrom (ASTM), the newest version prospectus
May 14, 2013
Subject to Completion, dated 5/13/13   On 5/9/13, ASTM received notice from NASDAQ that they have 180 calendar days, or until 11/5/13, to maintain the listing on the NASDAQ Capital Market. From the... Read More
category Henry McCusker
from Bio-Wire.Com
Aastrom (ASTM) Notice of Delisting
May 13, 2013
Notice of Failure to Satisfy a Continued Listing Rule or Standard   On 5/9/13, Aastrom Biosciences received a notification letter from NASDAQ ‘s Listing Qualifications Department advising that for the... Read More
category Henry McCusker
from Bio-Wire.Com
Aastrom (ASTM) Q1/13 Results – Don’t Just Sell – RUN
May 09, 2013
 Net loss of $6.8 M, or $0.15 per share   A net loss of $6.8 million, or $0.15 per share for Q1/13, compared to a net loss  of $9.7 million, or $0.25 per share for Q1/12. The decrease in net loss is... Read More
category Henry McCusker
from Bio-Wire.Com
Aastrom Biosciences, Inc. (ASTM) Posts Q1 Loss of 15c/Share
May 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8319165 for the full story. Read More
from StreetInsider.com News Articles
Aastrom Biosciences: New 52-Week Low Set Today (ASTM)
April 30, 2013
from Comtex SmarTrend® News Briefs
Stock to Watch: Aastrom Biosciences Down 8.7% (ASTM)
April 29, 2013
from Comtex SmarTrend® News Briefs
Aastrom Biosciences: New 52-Week Low Set Today (ASTM)
April 29, 2013
from Comtex SmarTrend® News Briefs
Stocks Hitting 52-Week Lows
April 29, 2013
Auxilium Pharmaceuticals (NASDAQ: AUXL ) shares tumbled 7.86% to touch a new 52-week low of $14.77. Auxilium Pharmaceuticals reported a Q1 non-GAAP net loss of $2.3 million. Aastrom Biosciences... Read More
category Benzinga , AUXL , 52/Week Lows , and 7 more.
from Latest Articles from Benzinga.com
Aastrom (ASTM) files S-1 for a full marketed follow-on with no warrants
April 29, 2013
With JMP on the cover – so far The “proposed” maximum aggregate offering is 25 M shares Prospectus can be accessed: http://investors.aastrom.com/secfiling.cfm?filingID=1104659-13-33806&CIK=887359. ASTM... Read More
category Henry McCusker
from Bio-Wire.Com
Aastrom Biosciences (ASTM) Files $25M Common Stock Shelf
April 29, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8284512 for the full story. Read More
from StreetInsider.com News Articles
Aastrom Biosciences (ASTM) First Patient Treated in DCM Clinical Study
April 19, 2013
     Of ixmyelocel-T ASTM first patient was treated in the ixCELL-DCM P2b clinical trial. This study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced... Read More
category Henry McCusker
from Bio-Wire.Com
Companies that Can Mend the Biotech Market: Stephen Brozak
April 11, 2013
Companies that Can Mend the Biotech Market: Stephen Brozak Source: George S. Mack of The Life Sciences Report (4/11/13) http://www.thelifesciencesreport.com/pub/na/15141 Markets are not efficient?at... Read More
category BTX , ASTM , ALXA , and 9 more.
from Bio-Wire.Com
Aastrom (ASTM), The Analyst Downgrade List
April 09, 2013
Updating the firms   I-Banks and research firms that have changed their ratings and price targets for Aastrom Biosciences (ASTM) during the last 10 days:   Downgraded at Roth Capital from a “Neutral”... Read More
category Henry McCusker , ASTM
from Bio-Wire.Com
RegMed Sector, this market has 2 stories – confused and nervous for good reason
April 04, 2013
End of Day, Cause and Effect                                                                                   RegMed stocks wavered on either side of neutral [...] Read More
category Henry McCusker
from Bio-Wire.Com
Aastrom Biosciences (ASTM), 1st P2 DCM patient but a $7+ M initial cost – still a SELL
April 04, 2013
First patients have been enrolled in the ixCELL-DCM clinical trial   This P2b study is currently underway in the US to assess the … efficacy and safety of ixmyelocel-T in the treatment of patients with... Read More
category Henry McCusker , ASTM
from Bio-Wire.Com
Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T
April 04, 2013
Aastrom Biosciences, Inc. (Nasdaq: ASTM ), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that... Read More
category Benzinga , ASTM , News , and 1 more.
from Latest Articles from Benzinga.com
RegMed Sector, humpty dumpty fell off the wall … where are all the King’s men to put him together again?
April 03, 2013
End of Day, Cause and Effect                                                                                   RegMed stocks accelerated their losses post midday trading Wednesday, [...] Read More
category Henry McCusker
from Bio-Wire.Com
RegMed sector, lower open expected
April 01, 2013
Stocks seen starting Q2 slightly lower   Stock index futures pointed to a flat to slightly lower open on Monday as investors geared up for the first day of trade after a long Easter weekend. It was a... Read More
category Henry McCusker , google , OTC BB:ACTC/OB , and 47 more.
from Bio-Wire.Com
Stocks Hitting 52-Week Lows
March 28, 2013
Garmin (NASDAQ: GRMN ) shares touched a new 52-week low of $32.81. Garmin's PEG ratio is 2.08. Aastrom Biosciences (NASDAQ: ASTM ) shares reached a new 52-week low of $0.67. Analysts at Needham... Read More
category OSUR , Benzinga , 52/Week Lows , and 7 more.
from Latest Articles from Benzinga.com
Cytori CYTX) Patents Method of Treating Renal Diseases
March 28, 2013
CKD is an important co-morbidity of cardiovascular disease   CYTX received US Patent No. 8,404,229 (the ’229 patent) for methods of treating renal diseases using adipose-derived regenerative cells... Read More
category Henry McCusker , google , OTC BB:ACTC/OB , and 48 more.
from Bio-Wire.Com
NeoStem, Inc. (NYSE MKT: NBS) VSEL funding continued
March 28, 2013
VSELs might be an ideal cell therapy to regenerate the body’s immune system and repair other tissues damaged by radiation exposure   NBS has been awarded the 2nd year of a 2 year grant totaling... Read More
category Henry McCusker , google , OTC BB:ACTC/OB , and 48 more.
from Bio-Wire.Com
Downgrade Alert for Aastrom Biosciences (ASTM)
March 28, 2013
from Comtex SmarTrend® News Briefs
Aastrom’s (ASTM) huge disappointment and a dwindling wallet
March 27, 2013
ASTM under-weighed the risk adjustment of trial recruitment and management musical chairs #160; First, the P3 CLI trial testing was an absolute failure but pre-ordained! On 5/9/12, ASTM noted the 1st... Read More
category Henry McCusker
from Bio-Wire.Com
Aastrom’s (ASTM) huge disappointment and a dwindling wallet
March 27, 2013
ASTM under-weighed the risk adjustment of trial recruitment and management musical chairs   First, the P3 CLI trial testing was an absolute failure but pre-ordained! On 5/9/12, ASTM noted the 1st... Read More
category Henry McCusker , google , OTC BB:ACTC/OB , and 48 more.
from Bio-Wire.Com
Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE CLI
March 27, 2013
In a report published Wednesday, Oppenheimer analyst Boris Peaker reiterated a Perform rating on Aastrom Biosciences (NASDAQ: ASTM ). In the report, Peaker noted, “Earlier today, Aastrom announced that... Read More
category Reiteration , Oppenheimer , Benzinga , and 3 more.
from Latest Articles from Benzinga.com
Notable 52-Week Highs and Lows of the Day 03/27: (SAI) (GILD) (LNG) High; (CLF) (ZIOP) (ASTM) Low
March 27, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8215306 for the full story. Read More
from StreetInsider.com News Articles
Unusual 11 Mid-Day Movers 03/27: (CHCI) (UEPS) (UTSI) Higher; (ASTM) (EVBS) (CLF) Lower
March 27, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8215168 for the full story. Read More
from StreetInsider.com News Articles
Aastrom Biosciences Ends Clinical Study
March 27, 2013
Aastrom Biosciences Inc. (Nasdaq: ASTM) will end development of its critical limb ischemia treatment. The stock price plunged 44 cents to $0.71.  ... Read More
from MarketMinute.com Stock News
Hot Stock: Aastrom Biosciences, Shares Drop 33.9% (ASTM)
March 27, 2013
from Comtex SmarTrend® News Briefs
Cyprus Concerns Weigh Down Markets
March 27, 2013
Concerns about Cyprus weighed the markets down to a lower open with the Dow dropping 78 points to 14,480. Nasdaq fell 20 points to 3232. Read More
category Market News
from MarketMinute.com Market Updates
< Previous 1 2 3 4 5 6 7 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here